What is claimed is:

1. A delivery device for treatment of erectile dysfunction in a patient, comprising a disk formed from a filmogenic polymer, and having an effective dose of a therapeutic agent suitable for reversing erectile dysfunction.

2. A delivery device according to claim 1, comprising further at least one additive contained within the disk, wherein the at least one additive is selected from the group consisting of a stabilizer, a solubilizer, an enhancer and a plasticizer.

3. A delivery device according to claim 1, wherein the therapeutic agent is a prostaglandin.

4. A delivery agent according to claim 3, wherein the prostaglandin is prostaglandin E1.

5. A delivery device according to claim 1, wherein the therapeutic agent is selected from the group consisting of: a vasodilator, a smooth muscle relaxant, an anti-depressant, a parasympathetic stimulator, a renin-angiotensin system inhibitor, a local anesthetic, an α-blocker, and a calcium channel blocker.

6. A delivery device according to claim 5, comprising further at least an additional therapeutic agent.

7. A delivery device according to claim 6, wherein the at least additional therapeutic agent is selected from the group consisting of: a prostaglandin, a testosterone, a yohimbine, a pentoxifylline, a trazodone, an apomorphine, a phentolamine, a sildenafil, a minoxidil, a misoprostol, a papaverine, a nitroglycerin, a phentolamine, a moxisylyte, a linsidomine, a linear peptide, a cyclic peptide, and a pyridylguanidine compound.

8. A delivery device according to claim 2, wherein the enhancer is at least one selected from the group consisting of a glycolipid, a non-esterified fatty acid, an aliphatic alcohol, a fatty acid ester of an aliphatic alcohol, a cyclohexanol, a cyclohexanol derivative, a fatty acid ester of glycerol, a glycol, an aliphatic alcohol ether of a glycol, and a surfactant.

9. A delivery device according to claim 8, wherein the filmogenic polymer is polyvinyl pyrrolidone, the therapeutic agent is prostaglandin E1, the enhancer is Eutanol G16S, and the plasticizer is PEG 400.

10. A delivery device according to claim 2, wherein the filmogenic material is present in an amount of 5 to 100%, the therapeutic agent is present in an amount of 0.1 to 20% w/w, the enhancer is present in an amount of 0.01 to 15%, and the plasticizer is present in an amount of 1 to 70%, each on a weight basis.

11. A delivery device according to claim 10, having the filmogenic material present in an amount of 5 to 50%, the therapeutic agent present in an amount of 1 to 10%, the permeation enhancer present in an amount of 1 to 10%, and the plasticizer present in an amount of 3 to 50%.

12. A delivery device according to claim 9, having polyvinyl pyrrolidone present in an amount that is 40 to 45%, having prostaglandin E1 present in an amount that is 5 to 10%, having Eutanol G16S present in an amount that is 1 to 4%, and having PEG 400 present in an amount that is 40 to 50%.

13. A delivery device according to claim 1, wherein the filmogenic polymer is selected from the group consisting of a synthetic polymer, a semi-synthetic polymer, and a naturally occurring polymer.

14. A delivery device according to claim 13, wherein the synthetic polymer is polyvinyl pyrrolidone.

15. A delivery device according to claim 13, wherein the naturally occurring polymer is from a plant.

16. A delivery device according to claim 15, wherein the plant polymer is a gliadin.

17. A delivery device according to claim 2, having a plasticizer in an amount less than 30% on a dry weight basis, and forming a rigid disk.

18. A delivery device according to claim 1, wherein delivery is transdermal.

19. A delivery device according to claim 1, wherein delivery is transmucosal.

20. A delivery device according to claim 1, wherein the effective dose is released into the subject within one hour.

21. A method of treating erectile dysfunction, comprising:

selecting a disk formed from a filmogenic polymer and comprising one or more therapeutic agents selected from the group consisting of a vasodilator, a smooth muscle relaxant, an anti-depressant, a parasympathetic stimulator, a renin-angiotensin system inhibitor, a local anesthetic, an α-blocker, and a calcium channel blocker; and

delivering the therapeutic agent to the penile surface over an effective period of time.

22. A method according to claim 21, wherein in forming the disk, the therapeutic agent is selected from the group consisting of a prostaglandin, a testosterone, a yohimbine, a pentoxifylline, a trazodone, an apomorphine, a phentolamine, a sildenafil, a minoxidil, a misoprostol, a papaverine, a nitroglycerin, a phentolamine, a moxisylyte, a linsidomine, a linear peptide, a cyclic peptide, and a pyridylguanidine compound.

23. A method according to claim 21, wherein the therapeutic agent is present in a range of 0.1-15%, on a dry weight basis.

24. A method according to claim 21, wherein forming the disk further comprises adding a plasticizer.

25. A method according to claim 24, wherein the plasticizer is present in an amount that is 30 to 60% on a dry weight basis, and delivering the therapeutic agent to the penile surface does not require pre-wetting.

26. A method according to claim 24, wherein the plasticizer is present in an amount that is less than 30% on a dry weight basis, and delivering the therapeutic agent to the penile surface has the additional step of pre-wetting the surface.

27. A method according to claim 24, wherein the plasticizer is a polyethylene glycol (PEG).

28. A method according to claim 27, wherein the PEG is PEG 400.

29. A method according to claim 21, wherein the filmogenic polymer is a synthetic polymer.

30. A method according to claim 29, wherein the synthetic polymer is polyvinyl pyrrolidone.

31. A method according to claim 21, wherein the filmogenic polymer is a plant protein.

32. A method according to claim 23, wherein the plant protein is a prolamine.

33. A method according to claim 32, wherein the prolamine is a gliadin.

34. A method according to claim 21, wherein the effective period of time is 5-100 minutes.

35. A method according to claim 34, wherein the effective period of time is 30-60 minutes.

36. A method according to claim 21, wherein the penile surface is selected from the group consisting of the shaft and the glans.

37. A method of preparation of a flexible disk for treatment of erectile dysfunction, comprising:

preparing a composition having prostaglandin E1, Eutanol G16S, PVP, and PEG 400; and

forming the composition to have a backing and a release layer.

38. A method according to claim 37, wherein preparing the composition includes adding prostaglandin E1 in an amount that is 5 to 10%, adding Eutanol G16S in an amount that is 1 to 5%, adding polyvinyl alcohol pyrrolidone in an amount that is 40 to 50%, and adding PEG 400 in an amount that is 40 to 50%, each on a dry weight basis.